Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

61. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 19428097 2009 06 08 2009 06 26 2012 11 15 1097-6825 123 6 2009 Jun The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. 1342-8 10.1016/j.jaci.2009.03.015 Eye symptoms (...) with either placebo or fluticasone furoate nasal spray (FFNS). Subjects recorded their nasal and ocular symptoms, and nasal secretions were quantified. Nasal scrapings to quantify eosinophils were obtained before each antigen challenge. Nasal challenge with antigen led to sneezing, a nasonasal, and a nasal-ocular reflex. Priming in the number of sneezes, contralateral nasal secretion weights, and total eye symptoms were observed. Treatment with FFNS reduced sneezing, the nasonasal and nasal-ocular

EvidenceUpdates2009

63. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Oba Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess whether maintenance inhaled medication was cost-effective for patients with moderate-to-severe chronic obstructive pulmonary disease. The author concluded that, at willingness-to-pay thresholds over 52,800 US dollars per quality-adjusted life-year, combined fluticasone and salmeterol propionate therapy was most cost-effective, below this threshold no maintenance therapy, with bronchodilator use as needed, was most cost

NHS Economic Evaluation Database.2009

64. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to estimate the cost-effectiveness of the combination of fluticasone propionate and salmeterol compared with no maintenance treatment in chronic obstructive pulmonary disease. The authors concluded that both the combination and salmeterol alone were cost-effective compared

NHS Economic Evaluation Database.2009

66. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children.

Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. 19164187 2009 01 23 2009 01 27 2015 11 19 1533-4406 360 4 2009 Jan 22 The New England journal of medicine N. Engl. J. Med. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. 339-53 10.1056/NEJMoa0808907 Although virus-induced wheezing is common in preschool-age children, optimal management remains elusive. We examined the efficacy and safety of preemptive treatment with high (...) -dose fluticasone in reducing the severity of recurrent virus-induced wheezing in children. We randomly assigned 129 children who were 1 to 6 years of age to receive 750 microg of fluticasone propionate (ex-valve [manufacturer-measured] dose) or placebo twice daily, beginning at the onset of an upper respiratory tract infection and continuing for a maximum of 10 days, over a period of 6 to 12 months. The primary outcome was rescue oral corticosteroid use. Secondary outcomes included symptoms, use

NEJM2009

67. Fluticasone at different doses for chronic asthma in adults and children.

Fluticasone at different doses for chronic asthma in adults and children. BACKGROUND: Inhaled fluticasone propionate (FP) is a high-potency inhaled corticosteroid used in the treatment of asthma. OBJECTIVES: 1. To assess the efficacy and safety outcomes of inhaled fluticasone at different nominal daily doses in the treatment of chronic asthma.2. To test for the presence of a dose-response effect. SEARCH STRATEGY: We searched the Cochrane Airways Group Trials Register (January 2008). SELECTION (...) CRITERIA: Randomised trials in children and adults comparing fluticasone at different nominal daily doses in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One review author extracted data. These were checked and verified by a second reviewer. Quantitative analyses where undertaken using Review Manager. MAIN RESULTS: Fifty-one published and unpublished trials (representing 55 group comparisons

Cochrane2008

68. Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease

Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease Article Text Therapeutics Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

69. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients 18455221 2008 06 09 2008 07 01 2015 11 19 1097-6825 121 6 2008 Jun The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma (...) -dose inhaler and the fixed-dose fluticasone propionate/salmeterol DPI. This was a randomized, open-label, multicenter study of patients (N = 1225) 12 years and older with moderate-to-severe persistent asthma. After 10 to 14 days of current therapy, patients were randomized 2:1 to fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations [320/9 microg] twice daily) or fixed-dose fluticasone propionate/salmeterol (250/50 microg x 1 inhalation twice daily) for 1 month (treatment period 1), after which, the fixed

EvidenceUpdates2008

70. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.

Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. BACKGROUND: Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids. Fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against their respective monocomponents, but there is a need to compare these two therapies on a head (...) -to-head basis. OBJECTIVES: To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function. SEARCH STRATEGY: We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Searches are current to May 2008. SELECTION CRITERIA: Randomised studies comparing fixed dose FP/SAL and BUD/F were eligible, for a minimum

Cochrane2008

71. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma

Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma 18592826 2008 07 02 2008 08 18 2016 11 24 1081-1206 100 6 2008 Jun Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Ann. Allergy Asthma Immunol. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone (...) dry powder inhaler on exhaled inflammatory markers in childhood asthma. 601-7 10.1016/S1081-1206(10)60052-X Extra-fine hydrofluoroalkane-beclomethasone differs from other inhaled corticosteroids by its fine aerosol characteristics. Therefore, extra-fine hydrofluoroalkane-beclomethasone may be particularly useful for treating peripheral airway inflammation in asthma. To analyze the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler (DPI

EvidenceUpdates2008

72. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis

Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis 18517084 2008 06 03 2008 07 02 2015 11 19 1081-1206 100 5 2008 May Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Ann. Allergy Asthma Immunol. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. 497-505 10.1016/S1081 (...) -1206(10)60477-2 Intranasal corticosteroids are recommended as first-line therapy for the treatment of allergic rhinitis. Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of allergic rhinitis. To compare the efficacy and safety of intranasal fluticasone furoate with those of vehicle placebo nasal spray in adult and adolescent patients with perennial allergic rhinitis (PAR). After screening (7-14 days), patients 12 years and older with confirmed PAR were randomized

EvidenceUpdates2008

74. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children.

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. BACKGROUND: Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma. Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays. OBJECTIVES: To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma. SEARCH STRATEGY: We searched the Cochrane Airways (...) Group trial register (January 2007) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2006). SELECTION CRITERIA: Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed articles for inclusion and methodological quality. One

Cochrane2007

76. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma

Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma Li H T, Zhang T T, Zhou H, Qu X J, Wu W M (...) , Huang J CRD summary The authors concluded that combination therapy with a single salmeterol and fluticasone inhaler improved lung function and symptoms in patients with asthma, compared to increased doses of inhaled corticosteroids. It did not significantly reduce the risk of exacerbation. Although few details were reported about trial quality, the review was otherwise well conducted and these conclusions appear likely to be reliable. Authors' objectives To assess the effectiveness and safety

DARE.2007

77. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, Gosden T, Rudge H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to examine the cost-effectiveness of the salmeterol xinafoate and fluticasone propionate combination inhaler (SFC) compared with inhaled corticosteroids (ICS) for the treatment of chronic asthma in adults and children. The SFC was generally cost-effective in those with uncontrolled

NHS Economic Evaluation Database.2007

78. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. 17314337 2007 02 22 2007 03 01 2015 11 19 1533-4406 356 8 2007 Feb 22 The New England journal of medicine N. Engl. J. Med. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. 775-89 Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. We conducted (...) a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed. Of 6112 patients

NEJM2007

79. Veramyst (fluticasone furoate)

Veramyst (fluticasone furoate) Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Veramyst (fluticasone furoate) Company: GlaxoSmithKline NDA: 022051 Approval Date: 4/27/2007 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Administrative Document(s) and Correspondence (PDF) (PDF) (PDF) (PDF) Date created: November 3, 2008 Updated: July 16

FDA - Drug Approval Package2007

80. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Dyer M J, Halpin D M, Stein K CRD summary This review evaluated (...) ciclesonide and alternative inhaled corticosteroids for asthma in adults. It concluded that there is limited evidence that inhaled ciclesonide has similar effectiveness and efficacy to fluticasone and budesonide, but no clear evidence on side-effects. The conclusions about limited evidence seem reliable; further data may become available when identified studies reported as abstracts are published in full. Authors' objectives To review published randomised controlled trials (RCTs) of the effectiveness

DARE.2006